BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37589934)

  • 21. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
    Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
    Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of BET Bromodomain Inhibitor JQ1 on Double-Expressor Lymphoma Cell Lines and Its Mechanism].
    Chen XY; Yan X; Song BY; Sun J; Mu LJ; Li WP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1094-1100. PubMed ID: 35981367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment.
    Marchesi I; Fais M; Fiorentino FP; Bordoni V; Sanna L; Zoroddu S; Bagella L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis.
    Wang J; Zhou F; Li Z; Mei H; Wang Y; Ma H; Shi L; Huang A; Zhang T; Lin Z; Wu G
    Sci Rep; 2018 Jan; 8(1):998. PubMed ID: 29343723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis.
    Zhang MY; Liu SL; Huang WL; Tang DB; Zheng WW; Zhou N; Zhou H; Abudureheman T; Tang ZH; Zhou BS; Duan CW
    Med Sci Monit; 2020 Apr; 26():e923411. PubMed ID: 32266878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.
    Sengupta S; Biarnes MC; Clarke R; Jordan VC
    Breast Cancer Res Treat; 2015 Apr; 150(2):265-78. PubMed ID: 25721606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
    Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
    Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
    Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
    Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
    Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Aird F; Kandela I; Mantis C;
    Elife; 2017 Jan; 6():. PubMed ID: 28100400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
    Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ
    Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
    Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
    Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
    Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.